Affordable Access

Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.

Authors
  • Licitra, Edward J
  • Vyas, Viral
  • Nelson, Kathy
  • Musanti, Rita
  • Beers, Stephanie
  • Thomas, Cecilia
  • Poplin, Elizabeth
  • Smith, Sharon
  • Lin, Yong
  • Schaaf, Larry J
  • Aisner, Joseph
  • Gounder, Murugesan
  • Rajendra, Rajeev
  • Saleem, Ahamed
  • Toppmeyer, Deborah
  • Rubin, Eric H
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
May 01, 2003
Volume
9
Issue
5
Pages
1673–1679
Identifiers
PMID: 12738720
Source
Medline
License
Unknown

Abstract

Pharmacologically guided administration of etoposide in combination with irinotecan/cisplatin using a 21-day cycle is associated with acceptable toxicity and significant antitumor activity. The finding that PBMNC topoisomerase IIalpha protein levels increased after irinotecan/cisplatin treatment in two of six patients supports the continued development of sequential topoisomerase targeting in the treatment of malignancy.

Report this publication

Statistics

Seen <100 times